DK2994160T3 - Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g - Google Patents

Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g Download PDF

Info

Publication number
DK2994160T3
DK2994160T3 DK14730660.9T DK14730660T DK2994160T3 DK 2994160 T3 DK2994160 T3 DK 2994160T3 DK 14730660 T DK14730660 T DK 14730660T DK 2994160 T3 DK2994160 T3 DK 2994160T3
Authority
DK
Denmark
Prior art keywords
poolet
alzheimer
immunoglobulin
treatment
subpopulations
Prior art date
Application number
DK14730660.9T
Other languages
English (en)
Inventor
David M Gelmont
Julia Singer
Sandor Fritsch
Hans-Peter Schwarz
Original Assignee
Baxalta Inc
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Inc, Baxalta GmbH filed Critical Baxalta Inc
Application granted granted Critical
Publication of DK2994160T3 publication Critical patent/DK2994160T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39516—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum from serum, plasma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK14730660.9T 2013-05-06 2014-05-05 Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g DK2994160T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361855062P 2013-05-06 2013-05-06
US201361833447P 2013-06-10 2013-06-10
US201361844732P 2013-07-10 2013-07-10
US201361886464P 2013-10-03 2013-10-03
PCT/US2014/036848 WO2014182631A1 (en) 2013-05-06 2014-05-05 Treatment of alzheimer's disease subpopulations with pooled immunoglobulin g

Publications (1)

Publication Number Publication Date
DK2994160T3 true DK2994160T3 (da) 2019-08-12

Family

ID=50943566

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14730660.9T DK2994160T3 (da) 2013-05-06 2014-05-05 Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g

Country Status (12)

Country Link
US (3) US20140328856A1 (da)
EP (2) EP3552624A1 (da)
JP (1) JP6424210B2 (da)
AU (4) AU2014262890B2 (da)
DK (1) DK2994160T3 (da)
ES (1) ES2740127T3 (da)
HR (1) HRP20191383T1 (da)
HU (1) HUE044737T2 (da)
LT (1) LT2994160T (da)
PL (1) PL2994160T3 (da)
PT (1) PT2994160T (da)
WO (1) WO2014182631A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2941415A1 (en) 2014-03-21 2015-09-24 Alzheon, Inc. Methods for treating neurological disorders
US10568568B2 (en) * 2014-08-27 2020-02-25 Capnia, Inc. Methods for immune globulin administration
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
FI3347002T3 (fi) 2015-09-10 2023-08-10 Alzheon Inc Alzheimerin taudin hoitaminen tietyssä potilaspopulaatiossa
BR112018014762A2 (pt) * 2016-01-20 2018-12-26 Genentech Inc método de tratamento da doença de alzheimer (da) precoce
SMT202100666T1 (it) * 2016-08-18 2022-01-10 Alkahest Inc Frazioni di plasma sanguigno come trattamento per disturbi cognitivi associati all'invecchiamento
WO2018200560A1 (en) * 2017-04-26 2018-11-01 Alkahest, Inc. Dosing regimen for treatment of cognitive and motor impairments with blood plasma and blood plasma products
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
FI128916B (en) * 2018-02-05 2021-03-15 Vetcare Oy Health-promoting composition and method for its preparation
AU2020214796A1 (en) 2019-01-30 2021-07-29 Truebinding, Inc. Anti-Gal3 antibodies and uses thereof
KR102276545B1 (ko) * 2019-09-05 2021-07-15 고려대학교 산학협력단 Ct 영상 기반 부위별 대뇌 피질 수축율 예측 방법 및 장치
NL2024431B1 (en) 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
WO2021242776A2 (en) 2020-05-26 2021-12-02 Truebinding, Inc. Methods of treating inflammatory diseases by blocking galectin-3
EP4236988A4 (en) * 2020-10-30 2024-10-30 Rush University Medical Center INTRANASAL IMMUNOTHERAPY FOR THE TREATMENT OF ALZHEIMER'S DISEASE
WO2023150483A1 (en) * 2022-02-03 2023-08-10 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE348942B (da) 1970-06-02 1972-09-18 Statens Bakteriologiska Labor
US5624898A (en) 1989-12-05 1997-04-29 Ramsey Foundation Method for administering neurologic agents to the brain
US6585957B1 (en) 2000-01-25 2003-07-01 Aeropharm Technology Incorporated Medicinal aerosol formulation
CA2462682A1 (en) 2001-10-04 2003-04-10 Protein Therapeutics, Inc. The use of gammaglobulin for the treatment of immune-mediated diseases
US20090136505A1 (en) 2005-02-23 2009-05-28 Johanna Bentz Intranasal Administration of Active Agents to the Central Nervous System
NZ581205A (en) 2005-02-23 2011-06-30 Alza Corp Intranasal administration of active agents to the central nervous system
WO2007106617A2 (en) * 2006-01-30 2007-09-20 Talecris Biotherapeutics, Inc. Method of treatment and prophylaxis of diseases related to amyloid deposition using igm
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
MX2012003282A (es) 2009-09-17 2012-04-30 Baxter Healthcare Sa Co-formulacion estable de hialuronidasa e inmunoglobulina, y metodos de su uso.
US8622993B2 (en) 2009-12-18 2014-01-07 Healthpartners Research Foundation Device and method for delivering therapeutic substances to the maxillary sinus of a patient
TW201138807A (en) * 2010-04-13 2011-11-16 Baxter Int Use of ventricular enlargement rate in intravenous immunoglobulin treatment of Alzheimer's disease
AU2010353287A1 (en) * 2010-05-13 2012-11-29 The University Of Kentucky Research Foundation Treatment of MCI and Alzheimer's disease
CA2810731A1 (en) * 2010-09-17 2012-03-22 Baxter International Inc. Stabilization of immunoglobulins and other proteins through aqueous formulation with sodium chloride at weak acidic to neutral ph
KR20130139153A (ko) * 2011-01-18 2013-12-20 백스터 인터내셔널 인코포레이티드 인간 혈액 중 항-베타 아밀로이드 항체의 측정
TW201250247A (en) * 2011-04-01 2012-12-16 Baxter Int Use of cytokine levels in intravenous immunoglobulin treatment of Alzheimer's disease
DK2758076T3 (da) * 2011-09-24 2019-04-01 Csl Behring Gmbh Kombinationsterapi ved anvendelse af immunoglobulin og c1-inhibitor

Also Published As

Publication number Publication date
PL2994160T3 (pl) 2019-10-31
AU2019202459B2 (en) 2020-07-23
LT2994160T (lt) 2019-08-26
AU2019202459A1 (en) 2019-05-02
AU2024201051A1 (en) 2024-03-14
HRP20191383T1 (hr) 2020-02-07
EP2994160A1 (en) 2016-03-16
EP2994160B1 (en) 2019-07-03
AU2014262890B2 (en) 2019-01-31
AU2020257034A1 (en) 2020-11-12
AU2014262890A1 (en) 2015-11-26
JP6424210B2 (ja) 2018-11-14
PT2994160T (pt) 2019-08-07
US20210238267A1 (en) 2021-08-05
US20140328856A1 (en) 2014-11-06
EP3552624A1 (en) 2019-10-16
ES2740127T3 (es) 2020-02-05
JP2016518411A (ja) 2016-06-23
WO2014182631A1 (en) 2014-11-13
US20190144530A1 (en) 2019-05-16
HUE044737T2 (hu) 2019-11-28

Similar Documents

Publication Publication Date Title
DK2994160T3 (da) Behandling af alzheimers sygdom subpopulationer med poolet immunoglobulin g
IL285722A (en) Methods for treating alzheimer's disease
DK2968218T3 (da) Kombination til behandling af parkinsons sygdom
DK2955195T3 (da) Antisemaphorin-3a-antistof og behandling af alzheimers sygdom og inflammatoriske immunsygdomme ved anvendelse af samme
HUE053239T2 (hu) Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
IL244422A0 (en) Anti-b7-h1 antibodies for treating tumors
EP2970511A4 (en) INSULIN CONJUGATES incretin
DK3811943T3 (da) Forbindelse til anvendelse til behandling af øjenlidelser
EP2932645A4 (en) VALIDATION OF THE SAFETY OF A CENTRAL CLOUD APPLICATION
DK3010506T3 (da) Pridopidin i behandling af huntingtons sygdom
EP2956047A4 (en) IRIS EXPANDER
DK2968208T3 (da) Behandling af kataplexi
EP3065624A4 (en) AUTOMATED DETECTION OF EYE ALIGNMENT
EP2964658A4 (en) SUBSTITUTED ORGANOFLUORBORATES AS IMAGING AGENTS
EP2983654A4 (en) Treatment of cancer using coenzyme q10 combination therapies
EP3379317A4 (en) IMAGING LENS
EP2997047A4 (en) heparansulphates
EP3291722A4 (en) IMPROVED LENS OPPORTER
PL2961426T3 (pl) Leczenie zaburzeń ośrodkowego układu nerwowego przez donosowe podawanie immunoglobuliny g
EP2959219A4 (en) Class 1 compliant lens assembly
HUE059507T2 (hu) BAFF-ra és B7RP1-re specifikus fehérjék és alkalmazásuk
DK3024816T3 (da) Ppar-sparende forbindelser til behandling af metaboliske sygdomme
DK3041831T3 (da) Alfa-te-saltformer: sammensætninger og anvendelser til behandling af sygdom
EP2976864A4 (en) RECOMMENDATIONS
DK3066475T3 (da) Biomarkører for progression af alzheimers sygdom